89,447 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Bought by Principal Financial Group Inc.

Principal Financial Group Inc. acquired a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 89,447 shares of the company’s stock, valued at approximately $808,000. Principal Financial Group Inc. owned approximately 0.32% of Delcath Systems at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Rosalind Advisors Inc. lifted its position in shares of Delcath Systems by 155.1% during the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock valued at $22,184,000 after purchasing an additional 1,611,561 shares in the last quarter. AIGH Capital Management LLC lifted its position in shares of Delcath Systems by 1.7% during the 2nd quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock worth $20,086,000 after buying an additional 40,064 shares in the last quarter. BVF Inc. IL boosted its stake in shares of Delcath Systems by 23.1% in the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock worth $5,734,000 after buying an additional 225,918 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Delcath Systems by 31.0% in the first quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after acquiring an additional 161,678 shares in the last quarter. Finally, Shellback Capital LP purchased a new stake in shares of Delcath Systems during the second quarter valued at approximately $1,353,000. 61.12% of the stock is currently owned by institutional investors.

Delcath Systems Price Performance

Shares of NASDAQ DCTH opened at $9.76 on Friday. The business’s fifty day moving average price is $9.68 and its 200-day moving average price is $8.64. Delcath Systems, Inc. has a one year low of $2.60 and a one year high of $12.88. The stock has a market capitalization of $312.07 million, a PE ratio of -7.23 and a beta of 0.75.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on DCTH shares. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Canaccord Genuity Group restated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. Stephens restated a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.